Voyager Therapeutics, a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, has announced an update to its VY-AADC program for advanced Parkinson’s disease.
A major international collaboration involving hundreds of researchers worldwide has identified seventy-two new genetic variants that contribute to the risk of developing breast cancer.
Incyte and MacroGenics have entered into an exclusive global collaboration and license agreement for MacroGenics’ MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1).
Aurinia Pharmaceuticals revealed plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD).
TARGET PharmaSolutions announced that Boehringer Ingelheim International has entered into a multi-year strategic partnership for TARGET-NASH.
Alnylam Pharmaceuticals has announced an exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus (HBV) infection.
UK’s National Institute for Health and Care Excellence (NICE) has made nivolumab (Opdivo) made by Bristol-Myers Squibb available for patients with head and neck cancer who did not respond to chemotherapy within six months, and the cancer has spread to other parts of the body.
A team of researchers at Moffitt Cancer Center used cellular drug screening, functional proteomics and computer-based modeling to determine whether drugs with well-known targets may be repurposed for use against other biological targets.
PanOptica a private biopharmaceutical company focused on developing innovative ophthalmology therapies, announced that it has secured $11m in a series B financing.
Visterra has completed a series C financing round raising a total of $46.7m, including a new extension totaling $23.6m.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.